Cell-based Therapies for Acute Respiratory Distress Syndrome : Where Are We Now?
There is considerable interest in the potential for cell-based therapies, particularly mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory distress syndrome (ARDS). MSCs exert effects via diverse mechanisms including reducing excessive inflammation by modulating neutrophil, macrophage and T-cell function, decreasing pulmonary permeability and lung edema, and promoting tissue repair. Clinical studies indicate that MSCs are safe and well tolerated, with promising therapeutic benefits in specific clinical settings, leading to regulatory approvals of MSCs for specific indications in some countries.This perspective reassesses the therapeutic potential of MSC-based therapies for ARDS given insights from recent cell therapy trials in both COVID-19 and in 'classic' ARDS, and discusses studies in graft-vs.-host disease, one of the few licensed indications for MSC therapies. We identify important unknowns in the current literature, address challenges to clinical translation, and propose an approach to facilitate assessment of the therapeutic promise of MSC-based therapies for ARDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:209 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 209(2024), 7 vom: 01. Apr., Seite 789-797 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Curley, Gerard F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS therapies |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 07.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1164/rccm.202311-2046CP |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368132099 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368132099 | ||
| 003 | DE-627 | ||
| 005 | 20240407232311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.202311-2046CP |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1368.xml |
| 035 | |a (DE-627)NLM368132099 | ||
| 035 | |a (NLM)38324017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Curley, Gerard F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cell-based Therapies for Acute Respiratory Distress Syndrome |b Where Are We Now? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 07.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There is considerable interest in the potential for cell-based therapies, particularly mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory distress syndrome (ARDS). MSCs exert effects via diverse mechanisms including reducing excessive inflammation by modulating neutrophil, macrophage and T-cell function, decreasing pulmonary permeability and lung edema, and promoting tissue repair. Clinical studies indicate that MSCs are safe and well tolerated, with promising therapeutic benefits in specific clinical settings, leading to regulatory approvals of MSCs for specific indications in some countries.This perspective reassesses the therapeutic potential of MSC-based therapies for ARDS given insights from recent cell therapy trials in both COVID-19 and in 'classic' ARDS, and discusses studies in graft-vs.-host disease, one of the few licensed indications for MSC therapies. We identify important unknowns in the current literature, address challenges to clinical translation, and propose an approach to facilitate assessment of the therapeutic promise of MSC-based therapies for ARDS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ARDS therapies | |
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a mesenchymal stem cells | |
| 650 | 4 | |a mesenchymal stromal cells | |
| 700 | 1 | |a O'Kane, Cecilia M |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a Matthay, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Laffey, John G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d 1994 |g 209(2024), 7 vom: 01. Apr., Seite 789-797 |w (DE-627)NLM074657305 |x 1535-4970 |7 nnns |
| 773 | 1 | 8 | |g volume:209 |g year:2024 |g number:7 |g day:01 |g month:04 |g pages:789-797 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.202311-2046CP |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 209 |j 2024 |e 7 |b 01 |c 04 |h 789-797 | ||